Galectin-3 plasma levels and coronary artery disease

A new possible biomarker of acute coronary syndrome

Colombo Falcone, S. Lucibello, I. Mazzucchelli, S. Bozzini, A. D'Angelo, S. Schirinzi, R. Totaro, R. Falcone, M. Bondesan, G. Pelissero

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Inflammation plays a key role in atherosclerosis. Galectin-3 is a macrophage- and endothelium-derived mediator actively involved in the regulation of many aspects of inflammatory cell behaviour. The aim of this study is to quantify plasma Galectin-3 in patients with coronary artery disease (CAD) and different clinical manifestation at the moment of observation in order to verify whether Galectin-3 could be a useful biomarker of atherosclerotic state. We enrolled 125 patients affected by CAD, angiographically documented (70 stable, 55 unstable). They underwent accurate examinations and anamnestic data was collected. The most important traditional risk factors, such as age, hypertension, and body mass index, were reported. Plasma Galectin-3 was quantified using an ELISA kit. Unstable patients (n = 55) had a higher plasma Galectin-3 levels in respect to the stable subjects (27.75 ng/mL (19.27-39.09) vs 6.48 ng/ml (4.88-8.83), p

Original languageEnglish
Pages (from-to)905-913
Number of pages9
JournalInternational Journal of Immunopathology and Pharmacology
Volume24
Issue number4
Publication statusPublished - Oct 2011

Fingerprint

Galectin 3
Acute Coronary Syndrome
Coronary Artery Disease
Biomarkers
Endothelium
Atherosclerosis
Body Mass Index
Enzyme-Linked Immunosorbent Assay
Macrophages
Observation
Hypertension
Inflammation

Keywords

  • CAD
  • Galectin-3
  • Stable and unstable angina

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Falcone, C., Lucibello, S., Mazzucchelli, I., Bozzini, S., D'Angelo, A., Schirinzi, S., ... Pelissero, G. (2011). Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome. International Journal of Immunopathology and Pharmacology, 24(4), 905-913.

Galectin-3 plasma levels and coronary artery disease : A new possible biomarker of acute coronary syndrome. / Falcone, Colombo; Lucibello, S.; Mazzucchelli, I.; Bozzini, S.; D'Angelo, A.; Schirinzi, S.; Totaro, R.; Falcone, R.; Bondesan, M.; Pelissero, G.

In: International Journal of Immunopathology and Pharmacology, Vol. 24, No. 4, 10.2011, p. 905-913.

Research output: Contribution to journalArticle

Falcone, C, Lucibello, S, Mazzucchelli, I, Bozzini, S, D'Angelo, A, Schirinzi, S, Totaro, R, Falcone, R, Bondesan, M & Pelissero, G 2011, 'Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome', International Journal of Immunopathology and Pharmacology, vol. 24, no. 4, pp. 905-913.
Falcone, Colombo ; Lucibello, S. ; Mazzucchelli, I. ; Bozzini, S. ; D'Angelo, A. ; Schirinzi, S. ; Totaro, R. ; Falcone, R. ; Bondesan, M. ; Pelissero, G. / Galectin-3 plasma levels and coronary artery disease : A new possible biomarker of acute coronary syndrome. In: International Journal of Immunopathology and Pharmacology. 2011 ; Vol. 24, No. 4. pp. 905-913.
@article{9b1b59b7e01f4069b41a6cc3af9b0c6c,
title = "Galectin-3 plasma levels and coronary artery disease: A new possible biomarker of acute coronary syndrome",
abstract = "Inflammation plays a key role in atherosclerosis. Galectin-3 is a macrophage- and endothelium-derived mediator actively involved in the regulation of many aspects of inflammatory cell behaviour. The aim of this study is to quantify plasma Galectin-3 in patients with coronary artery disease (CAD) and different clinical manifestation at the moment of observation in order to verify whether Galectin-3 could be a useful biomarker of atherosclerotic state. We enrolled 125 patients affected by CAD, angiographically documented (70 stable, 55 unstable). They underwent accurate examinations and anamnestic data was collected. The most important traditional risk factors, such as age, hypertension, and body mass index, were reported. Plasma Galectin-3 was quantified using an ELISA kit. Unstable patients (n = 55) had a higher plasma Galectin-3 levels in respect to the stable subjects (27.75 ng/mL (19.27-39.09) vs 6.48 ng/ml (4.88-8.83), p",
keywords = "CAD, Galectin-3, Stable and unstable angina",
author = "Colombo Falcone and S. Lucibello and I. Mazzucchelli and S. Bozzini and A. D'Angelo and S. Schirinzi and R. Totaro and R. Falcone and M. Bondesan and G. Pelissero",
year = "2011",
month = "10",
language = "English",
volume = "24",
pages = "905--913",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "4",

}

TY - JOUR

T1 - Galectin-3 plasma levels and coronary artery disease

T2 - A new possible biomarker of acute coronary syndrome

AU - Falcone, Colombo

AU - Lucibello, S.

AU - Mazzucchelli, I.

AU - Bozzini, S.

AU - D'Angelo, A.

AU - Schirinzi, S.

AU - Totaro, R.

AU - Falcone, R.

AU - Bondesan, M.

AU - Pelissero, G.

PY - 2011/10

Y1 - 2011/10

N2 - Inflammation plays a key role in atherosclerosis. Galectin-3 is a macrophage- and endothelium-derived mediator actively involved in the regulation of many aspects of inflammatory cell behaviour. The aim of this study is to quantify plasma Galectin-3 in patients with coronary artery disease (CAD) and different clinical manifestation at the moment of observation in order to verify whether Galectin-3 could be a useful biomarker of atherosclerotic state. We enrolled 125 patients affected by CAD, angiographically documented (70 stable, 55 unstable). They underwent accurate examinations and anamnestic data was collected. The most important traditional risk factors, such as age, hypertension, and body mass index, were reported. Plasma Galectin-3 was quantified using an ELISA kit. Unstable patients (n = 55) had a higher plasma Galectin-3 levels in respect to the stable subjects (27.75 ng/mL (19.27-39.09) vs 6.48 ng/ml (4.88-8.83), p

AB - Inflammation plays a key role in atherosclerosis. Galectin-3 is a macrophage- and endothelium-derived mediator actively involved in the regulation of many aspects of inflammatory cell behaviour. The aim of this study is to quantify plasma Galectin-3 in patients with coronary artery disease (CAD) and different clinical manifestation at the moment of observation in order to verify whether Galectin-3 could be a useful biomarker of atherosclerotic state. We enrolled 125 patients affected by CAD, angiographically documented (70 stable, 55 unstable). They underwent accurate examinations and anamnestic data was collected. The most important traditional risk factors, such as age, hypertension, and body mass index, were reported. Plasma Galectin-3 was quantified using an ELISA kit. Unstable patients (n = 55) had a higher plasma Galectin-3 levels in respect to the stable subjects (27.75 ng/mL (19.27-39.09) vs 6.48 ng/ml (4.88-8.83), p

KW - CAD

KW - Galectin-3

KW - Stable and unstable angina

UR - http://www.scopus.com/inward/record.url?scp=84856581939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856581939&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 905

EP - 913

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 4

ER -